IRIDEX

OverviewSuggest Edit

A worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 60 independent distributors into over 100 countries.
TypePublic
Founded1989
HQMountain View, CA, USMap
Websiteiridex.com
Employee Ratings3.4More
Overall CultureAMore
View Jobs (5)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)94(-17%)
Job Openings5
Revenue (FY, 2021)$36.3 M(-16%)
Share Price (Sept 2021)$7.2(-3%)
Cybersecurity ratingAMore

IRIDEX Office Locations

IRIDEX has an office in Mountain View
Mountain View, CA, US (HQ)
1212 Terra Bella Ave
Show all (1)

IRIDEX Financials and Metrics

IRIDEX Revenue

Embed Graph
View revenue for all periods
IRIDEX's revenue was reported to be $36.35 m in FY, 2021
USD

Revenue (FY, 2021)

36.3m

Gross profit (FY, 2021)

15.6m

Gross profit margin (FY, 2021), %

42.8%

Net income (FY, 2021)

(6.3m)

EBIT (FY, 2021)

(6.6m)

Market capitalization (14-Sept-2021)

111.7m

Closing stock price (14-Sept-2021)

7.2

Cash (2-Jan-2021)

11.6m

EV

104.3m
IRIDEX's current market capitalization is $111.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2021

Revenue

33.2m33.9m38.3m42.8m41.8m46.2m41.6m42.6m43.4m36.3m

Revenue growth, %

12%(2%)11%

Cost of goods sold

16.9m17.5m19.7m21.4m21.8m25.3m26.1m25.1m25.5m20.8m

Gross profit

16.3m16.3m18.6m21.4m20.0m20.8m15.5m17.5m17.9m15.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

10.8m10.8m8.3m8.4m7.9m8.9m9.2m9.5m10.3m10.6m10.1m9.8m10.8m9.0m11.9m11.9m9.8m10.5m10.0m10.9m9.5m10.3m11.3m10.6m10.4m10.7m9.0m

Cost of goods sold

5.9m5.9m4.3m4.3m4.0m4.7m4.7m4.8m5.3m5.3m5.0m5.0m5.4m4.8m6.6m6.2m5.5m6.0m5.5m6.5m5.6m6.0m6.7m6.3m5.9m6.4m5.1m

Gross profit

4.9m4.9m4.0m4.1m3.9m4.2m4.5m4.7m5.1m5.3m5.1m4.8m5.4m4.2m5.3m5.7m4.2m4.5m4.5m4.4m3.9m4.3m4.6m4.3m4.5m4.3m3.9m

Gross profit Margin, %

45%45%48%49%50%47%49%50%49%50%51%49%50%47%44%48%43%43%45%40%41%41%40%40%44%40%43%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2021

Cash

10.8m11.9m13.4m13.3m10.0m23.7m21.7m21.2m12.7m11.6m

Accounts Receivable

5.6m5.5m7.9m9.1m9.3m7.3m

Prepaid Expenses

464.0k1.1m500.0k547.0k401.0k730.0k

Inventories

6.7m8.0m10.6m9.1m11.1m11.6m9.4m8.8m8.2m5.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.9m9.5m13.9m13.8m13.7m11.6m13.5m14.1m14.0m12.9m13.0m10.2m13.1m12.2m10.5m11.5m9.6m23.9m24.6m22.8m18.5m16.0m23.7m17.2m15.6m12.9m11.1m11.6m

Accounts Receivable

7.5m7.7m5.1m5.9m5.5m6.0m6.1m5.7m6.7m7.3m9.3m8.5m7.9m8.9m7.0m7.4m6.4m7.1m8.4m8.4m8.1m8.8m7.0m5.8m

Prepaid Expenses

571.0k1.2m1.2m1.1m1.1m1.1m534.0k730.0k586.0k425.0k560.0k1.2m568.0k488.0k671.0k681.0k653.0k492.0k766.0k593.0k590.0k691.0k508.0k

Inventories

10.2m10.2m7.0m7.5m7.5m8.1m8.9m10.0m9.9m9.8m9.6m11.2m9.9m10.2m11.1m12.1m12.7m11.7m11.4m10.7m9.3m9.1m8.7m8.7m9.0m8.9m8.2m7.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2021

Net Income

2.6m1.4m2.2m10.0m474.0k(11.7m)(12.9m)(12.8m)(8.8m)(6.3m)

Depreciation and Amortization

410.0k427.0k490.0k420.0k522.0k648.0k858.0k809.0k688.0k504.0k

Inventories

(981.0k)(1.4m)(2.5m)1.5m(2.0m)(537.0k)2.1m463.0k545.0k2.4m

Accounts Payable

66.0k525.0k173.0k(520.0k)465.0k(229.0k)(270.0k)788.0k76.0k(1.4m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

1.5m1.8m1.6m1.9m1.2m874.0k1.3m1.8m487.0k784.0k490.0k442.0k246.0k(652.0k)101.0k(227.0k)(898.0k)(1.9m)(4.6m)(7.7m)(3.6m)(6.9m)(10.0m)(3.0m)(5.5m)(7.3m)(1.7m)(4.4m)

Depreciation and Amortization

203.0k307.0k113.0k203.0k310.0k126.0k240.0k364.0k108.0k239.0k142.0k291.0k461.0k207.0k417.0k660.0k193.0k395.0k617.0k211.0k354.0k518.0k143.0k277.0k

Inventories

(1.0m)(995.0k)(446.0k)(1.1m)(1.1m)(112.0k)(905.0k)(2.0m)747.0k852.0k9.6m11.2m9.9m10.2m(36.0k)(1.0m)(1.6m)(85.0k)255.0k974.0k75.0k282.0k533.0k66.0k(207.0k)(188.0k)(35.0k)278.0k

Accounts Payable

118.0k241.0k(36.0k)559.0k(51.0k)(825.0k)468.0k(28.0k)(508.0k)(270.0k)1.8m2.6m2.5m2.1m473.0k971.0k249.0k(50.0k)(214.0k)(130.0k)252.0k519.0k828.0k(116.0k)(320.0k)(86.0k)(1.1m)(2.0m)
show all
USDQ2, 2012

Financial Leverage

1.4 x
Show all financial metrics

IRIDEX Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

Learn more about our premium products
SecurityScorecard logo

IRIDEX Online and Social Media Presence

IRIDEX's Trends

Embed Graph

IRIDEX Company Culture

  • Overall Culture

    A

    89/100

  • CEO Rating

    A+

    85/100

  • Compensation

    A+

    100/100

Learn more on Comparably

IRIDEX News and Updates

August 09, 2021

Iridex to Present at the 2021 H.C. Wainwright Ophthalmology Virtual Conference

MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming H.C. Wainwright Ophthalm…
June 28, 2021

MicroPulse TLT after incisional glaucoma treatments

Our next webinar will be about dose escalation, durability, and the use of MicroPulse Transscleral Laser Therapy after MIGS, tubes, trabs, and other incisional glaucoma treatments. You are invited! June 29th at 5:00pm Pacific Time.
June 18, 2021

IRIDEX Corp. (IRIX) falls -3.9780% for June 18

IRIDEX Corp. (NASDAQ: IRIX) shares fell -3.9780% to end trading Friday at $7.00 per share - a net change of $-0.29. Shares traded between $7.52 and $7.00 throughout the day.
June 03, 2021

Partnership with the Wake Forest Baptist Eye Center to aid in a mission trip to the Lions Eye Hospital

We recently partnered with the Wake Forest Baptist Eye Center to aid in a mission trip to the Lions Eye Hospital in San Pedro Sula, Honduras. Physicians and staff from Wake Forest worked together with clinicians in Honduras to perform vital procedures on over 200 patients.
June 03, 2021

Webinar: The Management of AMD, CSR, and DME with MicroPulse Laser Therapy

Iridex is hosting a Webinar about "The Management of AMD, CSR, and DME with MicroPulse Laser Therapy." Join us to learn how experienced retina specialists are successfully treating age-related macular degeneration (AMD), central serous chorioretinopathy (CSR), and diabetic macular edema (DME) with l…
May 11, 2021

Iridex Announces First Quarter 2021 Financial Results

Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021.
Show more

IRIDEX Blogs

August 12, 2021

Iridex Announces Second Quarter 2021 Financial Results

Achieved 116% Year-over-Year Revenue Growth and Record Cyclo G6 Probe Sales Increases Full Year 2021 Guidance MOUNTAIN VIEW, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 3, 2021 .
July 29, 2021

Iridex to Report Second Quarter 2021 Financial Results on August 12, 2021

MOUNTAIN VIEW, Calif. , July 29, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of
May 11, 2021

Iridex Announces First Quarter 2021 Financial Results

Iridex Announces First Quarter 2021 Financial Results Content Import Tue, 05/11/2021 - 16:06 Iridex Announces First Quarter 2021 Financial Results 05/11/21 This release is a backfill from a News Wire Earnings MOUNTAIN VIEW, Calif., M…
April 27, 2021

Iridex to Report First Quarter 2021 Financial Results on May 11, 2021

MOUNTAIN VIEW, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of
March 08, 2021

Q4 2020 IRIDEX Earnings Conference Call

Q4 2020 IRIDEX Earnings Conference Call marco.guevara@… Mon, 03/08/2021 - 16:10 Q4 2020 IRIDEX Earnings Conference Call Display "add to calendar" true Event Type Earnings Conference Call Click here for webast …
November 09, 2020

IRIDEX Announces Third Quarter 2020 Financial Results

MOUNTAIN VIEW, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020 . Third Quarter Summary Total revenue of $8.8 million , a decline of 17% versus $10.7 million in the prior year period, and an
Show more

 IRIDEX Frequently Asked Questions

  • When was IRIDEX founded?

    IRIDEX was founded in 1989.

  • How many employees does IRIDEX have?

    IRIDEX has 94 employees.

  • What is IRIDEX revenue?

    Latest IRIDEX annual revenue is $36.3 m.

  • What is IRIDEX revenue per employee?

    Latest IRIDEX revenue per employee is $386.7 k.

  • Who are IRIDEX competitors?

    Competitors of IRIDEX include Lumibird, LPKF Laser & Electronics and Nisham Ariana.

  • Where is IRIDEX headquarters?

    IRIDEX headquarters is located at 1212 Terra Bella Ave, Mountain View.

  • Where are IRIDEX offices?

    IRIDEX has an office in Mountain View.

  • How many offices does IRIDEX have?

    IRIDEX has 1 office.